The Patent Act clearly stipulates that we are to review net prices, or, to be more precise, discounted prices, etc. We are currently holding consultations with both provincial and industry representatives to identify and assess these rebates.
Certain pharmaceutical companies seek to postpone their discounts because this reduces their average prices; on the other hand, there are many others, perhaps even the majority, that do not. It's an example of the push-pull concept.